TS-172 Phase 3 Hyperphosphatemia Study, Apr 23
Summary
A Phase 3 clinical trial registration for TS-172 (NCT07548840) in hyperphosphatemia patients receiving hemodialysis. The open-label, single-arm study will evaluate TS-172 at doses of 20-60 mg/day. ClinicalTrials.gov records this as a new study entry effective April 23, 2026, with hyperphosphatemia (elevated serum phosphate) as the condition and hemodialysis patients as the target population.
“An open-label, single-arm clinical study of TS-172 in hyperphosphatemia patients on hemodialysis”
About this source
ClinicalTrials.gov is the NIH-run registry of every clinical trial conducted in the United States, plus most international trials sponsored by US-based companies or institutions. By federal law, sponsors must register Phase 2 through Phase 4 studies before enrolling patients and post results within a year of completion. This feed tracks every new trial registration and study update, around 700 a month: drug interventions, device studies, behavioral protocols, observational research. Watch this if you scout drug candidates moving into mid or late-stage development, monitor competitor pipelines, or follow rare disease research where new trials signal patient hope. GovPing parses sponsor, phase, intervention, and target indication on each entry.
What changed
A new Phase 3 clinical trial (NCT07548840) for TS-172 has been registered on ClinicalTrials.gov by NIH as the sponsoring or responsible party. The study is an open-label, single-arm investigation evaluating TS-172 for the treatment of hyperphosphatemia in patients undergoing hemodialysis, with a proposed dosage of 20-60 mg/day. The record is effective as of April 23, 2026.
Affected parties include clinical investigators conducting nephrology or dialysis research, pharmaceutical companies developing phosphate-binding agents or CKD/end-stage renal disease treatments, and healthcare providers managing hemodialysis patients with elevated serum phosphate. Clinical trial registrations on ClinicalTrials.gov are informational records required for certain study types; they do not impose compliance obligations but serve as a public registry of ongoing research.
Archived snapshot
Apr 23, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
A Clinical Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis
Phase 3 NCT07548840 Kind: PHASE3 Apr 23, 2026
Abstract
An open-label, single-arm clinical study of TS-172 in hyperphosphatemia patients on hemodialysis
Conditions: Hyperphosphatemia Patients on Hemodialysis
Interventions: TS-172 20~60 mg/day
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.